Introduction

Paroxysmal Nocturnal Hemoglobinuria (PNH) and Aplastic Anaemia (AA) are both rare blood disorders that, even though they are different, share a deep and complex link. They are tied not only by how they work in the body but also in how they show up in the same person or change over time. This mix makes it hard for blood doctors all over the world to spot and treat these diseases. PNH is mostly seen as a disease where blood cells break apart and clots form, while AA is known for when the body's immune system stops the bone marrow from working. But new findings in cell science and the study of immunity have shown that these two illnesses are linked by a shared road of immune damage to the cells that make blood. Knowing this combined issue is key to fast finding, best care, and better health results for patients.

Overview of Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria is a rare blood illness that comes from changes in stem cells. Its three main signs are:

• Blood cells break up inside blood vessels
• Blood clots
• Bone marrow is not working well

The sickness starts from a change in the PIGA gene on the X chromosome. This gene is key for making GPI anchors, which hold certain proteins that protect cells, such as CD55 and CD59, to the cell surface. When PIGA has changed, affected stem cells can't make enough of these proteins. Because of this, red blood cells are easy to destroy by some parts of the immune system.¹

Clinical Signs of PNH

• Hemolysis as the main sign: The main sign of PNH is when red blood cells break down. This is known as hemolysis. People with PNH often wake up with dark urine, mostly because of this breakdown that happens more when they sleep
• Other common symptoms: Those with PNH may also feel very tired, have ongoing anaemia, belly pain, trouble swallowing, and muscle spasms in the throat. This happens because the broken-down red blood cells take up a gas in the body that is needed elsewhere²
• Thrombosis – a major health risk: The main health risk for PNH patients is thrombosis. This means blood clots happen where they shouldn't, like in the liver, gut, or brain's veins³
• Bone marrow failure: PNH can lead to bone marrow issues, where the body can't make enough new blood cells. This is often because PNH comes with other similar health problems

Overview of Aplastic Anaemia

Aplastic Anaemia

Aplastic Anaemia is when bone marrow does not work well. It is known by very few blood cells and less cell-making stuff in the bone, when there's no other illness or scarring. The illness is mostly because of immune system issues. Harmful immune cells hit the important stem cells in the bone marrow, sending out bad proteins that stop new blood cell formation and kill off existing ones in the marrow.⁴

Clinical Signs

• Fatigue and Pale Skin: The person feels very tired and looks very pale because of not having enough red blood cells
• Frequent Infections: They get sick often because they don't have enough white blood cells
• Bleeding or Bruising Easily: They may bleed or bruise easily due to not having enough platelets⁵

Diagnosis

The check for this involves taking a small bit of bone marrow to look at under a microscope, and it usually shows not much cell activity and more fat. Unlike PNH, breaking down red blood cells is not a common sign of this disease.

Shared Pathophysiology

The Link Between PNH and AA comes from how the immune system hurts stem cells. In aplastic anaemia, the immune system kills off the normal stem cells, which cuts down the mix of marrow clones. PNH clones, not having GPI-anchored proteins, might dodge immune notice and thus, live better. This choice in clone growth makes it so that a lot of patients with AA have small PNH clones, found by flow tests.⁶ Over time, these clones can grow, making PNH known.

On the flip side, for those first showing signs of PNH, a lasting immune hit and stress in the bone marrow can block blood cell making, leading to marrow failure. So, PNH and AA aren't two different sicknesses but are rather two ways the same immune-linked stem cell issue shows up.⁷ This overlapping biology explains why some patients develop both conditions simultaneously or evolve from one to the other.

Epidemiology and Prevalence of Dual Diagnosis

Both PNH and AA are rare disorders.

The count of AA cases is thought to be 2 to 3 in every million in the West each year. In Asia, and more so in Southeast Asia and China, it might be 5 to 7 per million.⁸

PNH is even less common, with about 1 to 2 people in every million getting it each year.⁹

Their mix is not rare. It is seen that 30 to 60% of those with AA also have small PNH groups, but few of them show big PNH signs. Also, 10 to 20% of those with PNH have signs of bone issues that fit with AA.¹⁰

Who gets these diseases? They often hit young people, with no clear link to being a guy or girl, but some might say PNH is more common in males.

Clinical Spectrum of PNH-AA Overlap Syndrome

Patients showing both PNH and AA signs vary a lot in how they feel. Some show strong signs of bone marrow not working well, like getting sick often, bleeding, and having very low red blood cell counts. Others show signs of red blood cells breaking down, like dark pee, belly pain, or blood clots. When cells break down, and there are also low blood cell counts, it leads to a range of unique health issues.

Blood clots are the biggest worry with PNH, and they are even more troubling when the patient also has bone marrow issues. Clots in the liver veins (Budd-Chiari syndrome), gut veins, and brain veins are common and can be deadly. These patients might also not have enough iron because of ongoing loss of blood in the urine. This iron loss can oddly make the cell breakdown less severe, but make the anaemia worse.¹¹ The diagnostic challenge lies in recognising that features of both disorders may coexist and require careful evaluation.

Diagnostic Approach

Diagnosing Overlap Syndrome

To find out if someone has overlap syndrome, doctors look at blood work, body chemicals, and cell types. Full blood checks often show low counts of all blood cells. Signs like high lactate dehydrogenase, indirect hyperbilirubinemia, and low haptoglobin point to PNH.

Gold Standard for Diagnosis

The best test is flow cytometry. It checks for missing proteins like CD55 and CD59 on red and white blood cells.¹² New, very good tests can find even tiny PNH clones, which matters a lot in AA patients since the clone might start small.

A bone marrow check is key to learn about the makeup of marrow cells. In AA, the marrow has few cells, but in typical PNH, the marrow might have normal or many cells, with signs of too many red blood cells.

Distinguishing between isolated PNH, isolated AA, and overlap is crucial. Patients with isolated AA show hypocellularity without hemolysis or large PNH clones. Patients with classical PNH have hemolysis, thrombosis, and preserved marrow function. Overlap cases demonstrate both significant marrow failure and hemolysis with detectable clones.

Treatment Strategies

The management of PNH-AA overlap syndrome is challenging and requires a tailored approach based on the dominant clinical features. Supportive care remains fundamental, including transfusions, iron supplementation, and infection prophylaxis.

• Immunosuppressive therapy (IST) is the main management for AA when it is associated with a few PNH groups. The use of both antithymocyte globulins and cyclosporines has shown good results, with 60-70% getting better. Having PNH groups in AA might link to a better answer to IST, maybe because these groups get less hit by the body's defence
• Complement inhibitors, mainly eculizumab and ravulizumab, have changed how we handle PNH greatly. By stopping complement part C5, these drugs stop blood cells from breaking inside blood vessels, cut down on the need for blood transfers, and greatly lower the chance of blood clots.¹⁴ In cases where the breaking of blood cells and blood clots is most seen, stopping the complement is key
• Hematopoietic stem cell transplantation (HSCT) is the only cure for both PNH and AA. It is mostly used in young people with a very bad disease, not helped by IST or made worse by blood clots. Better matching of donors and prep steps has made results a lot better, with people living longer than in 70% of cases¹⁵

In overlap cases, therapy often requires a combination of approaches. Patients may receive IST to restore marrow function while simultaneously being treated with complement inhibitors to control hemolysis and thrombosis. The choice of strategy depends on age, severity of cytopenias, clone size, and availability of transplant donors.

Prognosis and Long-Term Outcomes

Improved Outcomes for PNH-AA Patients

Over the last 20 years, the outlook for patients with PNH-AA has gotten much better thanks to new treatments like IST, drugs that block complement systems, and better results from transplants. Now, the rates of living five years after a diagnosis are between 70–80% in many cases.¹⁶

Yet, it's not all good news. Patients with big PNH cell groups face a greater danger of blood clots and red blood cell breakage. Those with very bad marrow failure have a high risk of dangerous infections and bleeding.

Long-term Health Issues

Some patients, particularly those who have had long-term marrow failure, may develop more severe conditions like MDS or AML. This is why keeping a close eye on these patients is crucial. Regular blood tests, checking for PNH cells with flow cytometry, and marrow checks are all key to catching problems early.

Research Advances and Future Directions

Recent work has made us know more about the PNH-AA link. New drugs like pegcetacoplan, a C3 blocker, seem good at handling both blood cell breakups inside and outside blood vessels.¹⁷ More new drugs that hit the early part of the chain in this path are being looked into.

We are learning more from DNA studies about other changes in genes beyond PIGA that may help in growing bad cells and making the illness worse. Also, better ways in HSCT, like matching from half-matched donors and using gentler prep steps, are making healing treatments more open and safer for more people. Adding these new treatments to care plans is seen to make results better in the next ten years.

Summary

Paroxysmal Nocturnal Hemoglobinuria (PNH) and Aplastic Anaemia are not common but are linked to blood disorders. They both happen due to harm caused by the immune system to blood-making cells, leading to the rise of PNH cells when the bone marrow fails.

Key points include:

Patients might show signs of both illnesses, which makes finding out what they have hard but key for the right care.

Treatment needs a one-of-a-kind plan, using methods to calm the immune system, stop certain proteins, and change blood cells.

Advances in therapy have significantly improved survival, but risks of thrombosis, infection, and clonal evolution remain. Future research into novel complement inhibitors and genetic drivers holds promise for even better outcomes.

FAQs

Can aplastic anaemia progress into paroxysmal nocturnal haemoglobinuria?

Yes. Up to 60% of patients with aplastic anaemia harbour small PNH clones detectable by flow cytometry. While not all progress to clinically significant disease, some patients eventually develop hemolysis and thrombotic complications typical of PNH. ⁶

Can PNH patients also develop aplastic anaemia?

Yes. About 10–20% of PNH patients develop features of bone marrow failure consistent with aplastic anaemia. This dual presentation is referred to as PNH-AA overlap syndrome.¹⁰

What is the best treatment for patients with both PNH and AA features?

Treatment depends on which clinical features predominate. Patients with severe marrow failure may benefit from immunosuppressive therapy, while those with hemolysis and thrombosis require complement inhibitors. In some cases, a combination of both approaches is needed, and hematopoietic stem cell transplantation may offer a cure.^13,15

Is PNH hereditary?

No. PNH is an acquired disorder caused by somatic mutations in the PIGA gene. It does not run in families, unlike some inherited marrow failure syndromes.¹

How has survival improved in recent years?

With the advent of complement inhibitors such as eculizumab and ravulizumab, alongside advances in stem cell transplantation and immunosuppressive therapy, five-year survival rates now exceed 70–80% for most patients with PNH-AA overlap. ¹⁶